PMID- 25038764
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140721
LR  - 20220318
IS  - 1598-2998 (Print)
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Linking)
VI  - 46
IP  - 3
DP  - 2014 Jul
TI  - Impact of hyperglycemia on survival and infection-related adverse events in 
      patients with metastatic colorectal cancer who were receiving palliative 
      chemotherapy.
PG  - 288-96
LID - 10.4143/crt.2014.46.3.288 [doi]
AB  - PURPOSE: Non-metastatic colorectal cancer patients with diabetes have poor 
      overall survival than those without diabetes. However, the effect of 
      hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) 
      has not been assessed. Therefore, we assessed the impact of hyperglycemia on the 
      survival and infection-related adverse events (AEs) in patients with metastatic 
      CRC. MATERIALS AND METHODS: We reviewed the records of 206 patients with newly 
      diagnosed metastatic CRC who were treated with palliative chemotherapy from March 
      2000 to December 2012 at Chungbuk National University Hospital. The mean glucose 
      level of each patient was calculated using all available glucose results. 
      RESULTS: The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and 
      patients were categorized into quartiles in accordance to their mean glucose 
      level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 
      mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in 
      groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; 
      however, this difference was not statistically significant (p=0.643). Compared 
      with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of 
      infection-related AEs, according to a multivariate analysis (p=0.002). 
      CONCLUSION: Hyperglycemia was not associated with shorter survival; however, it 
      was associated with infection-related AEs in patients with newly diagnosed 
      metastatic CRC receiving palliative chemotherapy.
FAU - Hong, Yong Joo
AU  - Hong YJ
AD  - Departments of Internal Medicine, Chungbuk National University College of 
      Medicine, Cheongju, Korea.
FAU - Han, Hye-Suk
AU  - Han HS
FAU - Jeong, Yusook
AU  - Jeong Y
FAU - Jeong, Jiwon
AU  - Jeong J
FAU - Lim, Sung-Nam
AU  - Lim SN
FAU - Choi, Hyung Jin
AU  - Choi HJ
FAU - Jeon, Hyun-Jung
AU  - Jeon HJ
FAU - Oh, Tae-Keun
AU  - Oh TK
FAU - Lee, Sang-Jeon
AU  - Lee SJ
FAU - Lee, Ki Hyeong
AU  - Lee KH
LA  - eng
PT  - Journal Article
DEP - 20140715
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
PMC - PMC4132450
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2014/07/21 06:00
MHDA- 2014/07/21 06:01
PMCR- 2014/07/01
CRDT- 2014/07/21 06:00
PHST- 2013/07/01 00:00 [received]
PHST- 2013/10/08 00:00 [accepted]
PHST- 2014/07/21 06:00 [entrez]
PHST- 2014/07/21 06:00 [pubmed]
PHST- 2014/07/21 06:01 [medline]
PHST- 2014/07/01 00:00 [pmc-release]
AID - crt-46-3-288 [pii]
AID - 10.4143/crt.2014.46.3.288 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2014 Jul;46(3):288-96. doi: 10.4143/crt.2014.46.3.288. Epub 
      2014 Jul 15.